Patents by Inventor Annie SHIN
Annie SHIN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240075129Abstract: Disclosed herein are methods for inducing immunity against a virus such as a coronavirus in the mucosal tissue of a patient, include administering a vaccine composition to the patient by oral administration (e.g., nasal injection, nasal inhalation, oral inhalation, and/or oral ingestion). Also disclosed are compositions for assaying the presence of anti-viral antibodies induced by the administered vaccine or the presence of viral proteins in a saliva sample include a stabilizing solution and may also include the use of aragonite particle beads. Compositions and methods are presented for prevention and/or treatment of a coronavirus disease wherein the composition comprises comprises a recombinant entity. The recombinant entity is bivalent, comprising a nucleic acid encoding a coronavirus 2 nucleocapsid protein CoV2 nucleocapsid protein fused to an endosomal targeting sequence, and a nucleic acid encoding a CoV2 spike protein sequence optimized for cell surface expression.Type: ApplicationFiled: October 17, 2023Publication date: March 7, 2024Applicant: ImmunityBio, Inc.Inventors: Patrick Soon-Shiong, Peter Sieling, Kayvan Niazi, Shahrooz Rabizadeh, Lise Geissert, Annie Shin, Adrian Rice, Elizabeth Gabitzsch, Jeffrey Safrit, Leonard Sender
-
Publication number: 20240018274Abstract: Compositions and methods are presented that allow for an enhanced immune response against a GPI-anchored tumor associated antigen by modification of the protein portion of the TAA to include a transmembrane domain and a trafficking signal that directs the modified protein to the endosomal or lysosomal compartment. Most preferably, the modified protein will no longer have a GPI anchor or GPI attachment sequence.Type: ApplicationFiled: June 21, 2023Publication date: January 18, 2024Inventors: Kayvan Niazi, Wael Tadros, Annie Shin
-
Patent number: 11857620Abstract: Disclosed herein are methods for inducing immunity against a virus such as a coronavirus in the mucosal tissue of a patient, include administering a vaccine composition to the patient by oral administration (e.g., nasal injection, nasal inhalation, oral inhalation, and/or oral ingestion). Also disclosed are compositions for assaying the presence of antiviral antibodies induced by the administered vaccine or the presence of viral proteins in a saliva sample include a stabilizing solution and may also include the use of aragonite particle beads. Compositions and methods are presented for prevention and/or treatment of a coronavirus disease wherein the composition comprises comprises a recombinant entity. The recombinant entity is bivalent, comprising a nucleic acid encoding a coronavirus 2 nucleocapsid protein CoV2 nucleocapsid protein fused to an endosomal targeting sequence, and a nucleic acid encoding a CoV2 spike protein sequence optimized for cell surface expression.Type: GrantFiled: March 10, 2021Date of Patent: January 2, 2024Assignee: ImmunityBio, Inc.Inventors: Patrick Soon-Shiong, Peter Sieling, Kayvan Niazi, Shahrooz Rabizadeh, Lise Geissert, Annie Shin, Adrian Rice, Elizabeth Gabitzsch, Jeffrey Safrit, Leonard Sender
-
Publication number: 20230338508Abstract: Disclosed herein are methods for inducing immunity against a virus such as a coronavirus in the mucosal tissue of a patient, include administering a vaccine composition to the patient by oral administration (e.g., nasal injection, nasal inhalation, oral inhalation, and/or oral ingestion). Also disclosed are compositions for assaying the presence of antiviral antibodies induced by the administered vaccine or the presence of viral proteins in a saliva sample include a stabilizing solution and may also include the use of aragonite particle beads. Compositions and methods are presented for prevention and/or treatment of a coronavirus disease wherein the composition comprises a recombinant entity. The recombinant entity is bivalent, comprising a nucleic acid encoding a coronavirus 2 nucleocapsid protein CoV2 nucleocapsid protein fused to an endosomal targeting sequence, and a nucleic acid encoding a CoV2 spike protein sequence optimized for cell surface expression.Type: ApplicationFiled: March 10, 2021Publication date: October 26, 2023Inventors: Patrick Soon-Shiong, Peter Sieling, Kayvan Niazi, Shahrooz Rabizadeh, Lise Geissert, Annie Shin, Adrian Rice, Elizabeth Gabitzsch, Jeffrey Safrit, Leonard Sender
-
Patent number: 11773187Abstract: Compositions and methods are presented that allow for an enhanced immune response against a GPI-anchored tumor associated antigen by modification of the protein portion of the TAA to include a transmembrane domain and a trafficking signal that directs the modified protein to the endosomal or lysosomal compartment. Most preferably, the modified protein will no longer have a GPI anchor or GPI attachment sequence.Type: GrantFiled: January 15, 2019Date of Patent: October 3, 2023Assignee: NantBio, Inc.Inventors: Kayvan Niazi, Wael Tadros, Annie Shin
-
Publication number: 20230183770Abstract: A method for the production of proteins used in the in vitro transcription (IVT) of messenger RNA (mRNA), wherein the proteins are evaluated for purity and efficacy by the efficiency with which mRNA synthetically derived therefrom, subsequently transfects cells and produces encoded proteins.Type: ApplicationFiled: September 12, 2022Publication date: June 15, 2023Inventors: Brett Morimoto, Kayvan Niazi, Annie Shin, Lise Geissert, Philip T. Liu
-
Publication number: 20230086390Abstract: Disclosed herein are methods for inducing immunity against a virus such as a coronavirus in the mucosal tissue of a patient, include administering a vaccine composition to the patient by oral administration (e.g., nasal injection, nasal inhalation, oral inhalation, and/or oral ingestion). Also disclosed are compositions for assaying the presence of antiviral antibodies induced by the administered vaccine or the presence of viral proteins in a saliva sample include a stabilizing solution and may also include the use of aragonite particle beads. Compositions and methods are presented for prevention and/or treatment of a coronavirus disease wherein the composition comprises a recombinant entity. The recombinant entity is bivalent, comprising a nucleic acid encoding a coronavirus 2 nucleocapsid protein CoV2 nucleocapsid protein fused to an endosomal targeting sequence, and a nucleic acid encoding a CoV2 spike protein sequence optimized for cell surface expression.Type: ApplicationFiled: March 10, 2021Publication date: March 23, 2023Inventors: Patrick Soon-Shiong, Peter Sieling, Kayvan Niazi, Shahrooz Rabizadeh, Lise Geissert, Annie Shin, Adrian Rice, Elizabeth Gabitzsch, Jeffrey Safrit, Leonard Sender
-
Publication number: 20230039169Abstract: Recombinant cells and methods therefor are contemplated that allow for rapid and high titer production of recombinant viruses, and especially replication deficient Ad5 virus. In some preferred aspects, the host cell is modified to produce an inhibitor that reduces or eliminates the expression of a therapeutic protein encoded in the virus, while in other aspects, the virus includes a gene that directly or indirectly reduces or eliminates the expression of a therapeutic protein encoded in the virus. Most preferably, shRNA encoded by the host cell will reduce or suppress expression of a payload gene encoded in the recombinant virus.Type: ApplicationFiled: September 15, 2022Publication date: February 9, 2023Inventors: Kayvan Niazi, Wael Tadros, Annie Shin
-
Patent number: 11485957Abstract: Recombinant cells and methods therefor are contemplated that allow for rapid and high titer production of recombinant viruses, and especially replication deficient Ad5 virus. In some preferred aspects, the host cell is modified to produce an inhibitor that reduces or eliminates the expression of a therapeutic protein encoded in the virus, while in other aspects, the virus includes a gene that directly or indirectly reduces or eliminates the expression of a therapeutic protein encoded in the virus. Most preferably, shRNA encoded by the host cell will reduce or suppress expression of a payload gene encoded in the recombinant virus.Type: GrantFiled: October 9, 2018Date of Patent: November 1, 2022Assignee: NantBio, Inc.Inventors: Kayvan Niazi, Wael Tadros, Annie Shin
-
Publication number: 20210284713Abstract: Compositions and methods are presented for prevention and/or treatment of a coronavirus disease wherein the composition comprises a recombinant entity. The recombinant entity comprises a nucleic acid that encodes a extracellular portion of CD40 ligand (CD40L) coupled by a flexible linker to a coronavirus 2 (CoV2) spike protein and/or a CoV2 nucleocapsid protein.Type: ApplicationFiled: October 28, 2020Publication date: September 16, 2021Inventors: Kayvan Niazi, Jay Gardner Nelson, Annie Shin, Clifford Anders Olson, Shiho Tanaka
-
Publication number: 20210032371Abstract: Compositions and methods are presented that allow for an enhanced immune response against a GPI-anchored tumor associated antigen by modification of the protein portion of the TAA to include a transmembrane domain and a trafficking signal that directs the modified protein to the endosomal or lysosomal compartment. Most preferably, the modified protein will no longer have a GPI anchor or GPI attachment sequence.Type: ApplicationFiled: January 15, 2019Publication date: February 4, 2021Inventors: Kayvan Niazi, Wael Tadros, Annie Shin
-
Publication number: 20200354687Abstract: Recombinant cells and methods therefor are contemplated that allow for rapid and high titer production of recombinant viruses, and especially replication deficient Ad5 virus. In some preferred aspects, the host cell is modified to produce an inhibitor that reduces or eliminates the expression of a therapeutic protein encoded in the virus, while in other aspects, the virus includes a gene that directly or indirectly reduces or eliminates the expression of a therapeutic protein encoded in the virus. Most preferably, shRNA encoded by the host cell will reduce or suppress expression of a payload gene encoded in the recombinant virus.Type: ApplicationFiled: October 9, 2018Publication date: November 12, 2020Applicant: NantBio, Inc.Inventors: Kayvan Niazi, Wael Tadros, Annie Shin
-
Publication number: 20200283531Abstract: Compositions, methods and uses of genetically modified NK cells to elicit immune response against cells infected with microorganisms are presented. In some embodiments, NK cells can be genetically modified with a recombinant nucleic acid that includes a segment encoding an extracellular single-chain variant fragment that specifically binds a CD1-lipid antigen complex and another segment encoding an intracellular activation domain, and a linker between those segments. In other embodiments, the NK cells can be genetically modified with a recombinant nucleic acid that includes a segment encoding an a chain T cell receptor and a ? chain T cell receptor, and another segment encoding at least a portion of CD3? and at least a portion of CD3?. The genetically modified NK cells can be administered to the patient infected with microorganism to trigger immune response specific to the cells infected with the microorganism.Type: ApplicationFiled: October 4, 2018Publication date: September 10, 2020Inventors: Kayvan Niazi, Marcos Sixto, Annie Shin, Phil Liu
-
Publication number: 20200282037Abstract: A pharmaceutical compositions and methods for immunotherapy are provided. The pharmaceutical composition includes a genetically-engineered bacterium expressing a human disease-related antigen(s), preferably two or more patient-specific tumor antigens as a polytope. The bacterium has genetically engineered lipopolysaccharide or a patient's own endosymbiotic bacterium so that the bacterium expresses endotoxin at a low level, which is insufficient to induce a CD-14 mediated sepsis. The genetically-engineered bacterium can be administered to the patient, either systemically or locally, to induce tumor-specific immune response.Type: ApplicationFiled: June 15, 2018Publication date: September 10, 2020Inventors: Kayvan NIAZI, Adam LAZAR, Philip T. LIU, Annie SHIN, Peter SIELING